Rational design of nasal vaccines

Journal of Drug Targeting

Volumn 16, Issue 1, 2008, Pages 1-17

  Slütter, Bram ^a   Hagenaars, Niels ^b   Jiskoot, Wim ^a,b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Adjuvant; M cell; Nanoparticle; Nasal vaccine delivery; Th1 Th2; Vaccination

Indexed keywords

ANTHRAX VACCINE; CANCER VACCINE; CHOLERA VACCINE; CPG OLIGODEOXYNUCLEOTIDE; ENTEROTOXIN; FLAGELLIN; HEPATITIS B VACCINE; HERPES VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; LIVE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; POLIOMYELITIS VACCINE; POLYMER; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 9; TYPHUS VACCINE; VACCINE; VIROSOME;

ANTIGEN PRESENTATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG TARGETING; HUMAN; INNATE IMMUNITY; INTESTINE CELL; LYMPHOID TISSUE; MEAN RESIDENCE TIME; MICROFOLD CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL;

ADMINISTRATION, INTRANASAL; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; VACCINATION; VACCINES;

EID: 38049087089     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860701637966     Document Type: Review

References (194)

1. Abe, N., Kodama, S., Hirano, T., Eto, M. and Suzuki, M. (2006) Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx. Laryngoscope, 116, pp. 407-412.
2. Ackerman, AL and Cresswell, P. (2004) Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol, 5, pp. 678-684.
3. Ackerman, AL, Kyritsis, C., Tampe, R. and Cresswell, P. (2005) Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells. Nat Immunol, 6, pp. 107-113.
4. Agrawal, S., Agrawal, A., Doughty, B., Gerwitz, A., Blenis, J., Van Dyke, T. and Pulendran, B. (2003) Cutting edge: Different toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol, 171, pp. 4984-4989.
5. Akira, S. and Takeda, K. (2004) Toll-like receptor signalling. Nat Rev Immunol, 4, pp. 499-511.
6. Amacker, M., Engler, O., Kammer, AR, Vadrucci, S., Oberholzer, D., Cerny, A. and Zurbriggen, R. (2005) Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int Immunol, 17, pp. 695-704.
7. Amidi, M., Romeijn, SG, Verhoef, JC, Junginger, HE, Bungener, L., Huckriede, A., Crommelin, DJ and Jiskoot, W. (2007) N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: Biological properties and immunogenicity in a mouse model. Vaccine, 25, pp. 144-153.
8. Arce, S., Nawar, HF, Russell, MW and Connell, TD (2005) Differential binding of Escherichia coli enterotoxins LT-IIa and LT-IIb and of cholera toxin elicits differences in apoptosis, proliferation, and activation of lymphoid cells. Infect Immun, 73, pp. 2718-2727.
9. Audouy, SA, van Selm, S., van Roosmalen, ML, Post, E., Kanninga, R., Neef, J., Estevao, S., Nieuwenhuis, EE, Adrian, PV, Leenhouts, K. and Hermans, PW (2007) Development of lactococcal GEM-based pneumococcal vaccines. Vaccine, 25, pp. 2497-2506.
10. Baca-Estrada, ME, Foldvari, M. and Snider, M. (1999) Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12. J Interferon Cytokine Res, 19, pp. 455-462.
11. Baca-Estrada, ME, Foldvari, MM, Snider, MM, Harding, KK, Kournikakis, BB, Babiuk, LA and Griebel, PP (2000) Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses. Vaccine, 18, pp. 2203-2211.
12. Barr, TA, Carlring, J. and Heath, AW (2006) Co-stimulatory agonists as immunological adjuvants. Vaccine, 24, pp. 3399-3407.
13. Belyakov, IM, Isakov, D., Zhu, Q., Dzutsev, A., Klinman, D. and Berzofsky, JA (2006) Enhancement of CD8 + T cell immunity in the lung by CpG oligodeoxynucleotides increases protective efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host. J Immunol, 177, pp. 6336-6343.
14. Bernkop-Schnurch, A., Kast, CE and Richter, MF (2001) Improvement in the mucoadhesive properties of alginate by the covalent attachment of cysteine. J Control Release, 71, pp. 277-285.
15. Bitsori, M., Ntokos, M., Kontarakis, N., Sianava, O., Ntouros, T. and Galanakis, E. (2005) Vaccination coverage among adolescents in certain provinces of Greece. Acta Paediatr, 94, pp. 1122-1125.
16. Blander, JM and Medzhitov, R. (2006) Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature, 440, pp. 808-812.
17. Bogataj, M., Vovk, T., Kerec, M., Dimnik, A., Grabnar, I. and Mrhar, A. (2003) The correlation between zeta potential and mucoadhesion strength on pig vesical mucosa. Biol Pharm Bull, 26, pp. 743-746.
18. Bowe, F., Lavelle, EC, McNeela, EA, Hale, C., Clare, S., Arico, B., Giuliani, MM, Rae, A., Huett, A., Rappuoli, R., Dougan, G. and Mills, KH (2004) Mucosal vaccination against serogroup B meningococci: Induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin. Infect Immun, 72, pp. 4052-4060.
19. Boyaka, PN, Lillard Jr., JW and McGhee, J. (1999) Interleukin 12 and innate molecules for enhanced mucosal immunity. Immunol Res, 20, pp. 207-217.
20. Boyaka, PN, Marinaro, M., Jackson, RJ, Menon, S., Kiyono, H., Jirillo, E. and McGhee, JR (1999) IL-12 is an effective adjuvant for induction of mucosal immunity. J Immunol, 162, pp. 122-128.
21. Bracci, L., Canini, I., Puzelli, S., Sestili, P., Venditti, M., Spada, M., Donatelli, I., Belardelli, F. and Proietti, E. (2005) Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine, 23, pp. 2994-3004.
22. Brandtzaeg, P. (1996) History of oral tolerance and mucosal immunity. Ann NY Acad Sci, 778, pp. 1-27.
23. Braun, MC, He, J., Wu, CY and Kelsall, BL (1999) Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression. J Exp Med, 189, pp. 541-552.
24. Bron, R., Ortiz, A. and Wilschut, J. (1994) Cellular cytoplasmic delivery of a polypeptide toxin by reconstituted influenza virus envelopes (virosomes). Biochemistry, 33, pp. 9110-9117.
25. Brooking, J., Davis, SS and Illum, L. (2001) Transport of nanoparticles across the rat nasal mucosa. J Drug Target, 9, pp. 267-279.
26. Bryant, ML, Brown, P., Gurevich, N. and McDougall, IR (1999) Comparison of the clearance of radiolabelled nose drops and nasal spray as mucosally delivered vaccine. Nucl Med Commun, 20, pp. 171-174.
27. Bungener, L., Huckriede, A., de Mare, A., de Vries-Idema, J., Wilschut, J. and Daemen, T. (2005) Virosome-mediated delivery of protein antigens in vivo: Efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine, 23, pp. 1232-1241.
28. Burgdorf, S., Kautz, A., Bohnert, V., Knolle, PA and Kurts, C. (2007) Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science, 316, pp. 612-616.
29. Carreno-Gomez, B., Woodley, JF and Florence, AT (1999) Studies on the uptake of tomato lectin nanoparticles in everted gut sacs. Int J Pharm, 183, pp. 7-11.
30. Cervi, L., MacDonald, AS, Kane, C., Dzierszinski, F. and Pearce, EJ (2004) Cutting edge: Dendritic cells copulsed with microbial and helminth antigens undergo modified maturation, segregate the antigens to distinct intracellular compartments, and concurrently induce microbe-specific Th and helminth-specific Th2 responses. J Immunol, 172, pp. 2016-2020.
31. Childers, NK, Miller, KL, Tong, G., Llarena, JC, Greenway, T., Ulrich, JT and Michalek, SM (2000) Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen. Infect Immun, 68, pp. 5509-5516.
32. Clark, MA, Jepson, MA and Hirst, BH (1995) Lectin binding defines and differentiates M-cells in mouse small intestine and caecum. Histochem Cell Biol, 104, pp. 161-168.
33. Clark, MA, Hirst, BH and Jepson, MA (1998) M-cell surface beta1 integrin expression and invasin-mediated targeting of Yersinia pseudotuberculosis to mouse Peyer's patch M cells. Infect Immun, 66, pp. 1237-1243.
34. Coeshott, CM, Smithson, SL, Verderber, E., Samaniego, A., Blonder, JM, Rosenthal, GJ and Westerink, MA (2004) Pluronic F127-based systemic vaccine delivery systems. Vaccine, 22, pp. 2396-2405.
35. Couch, RB (2004) Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N Engl J Med, 350, pp. 860-861.
36. Crockett, M. and Keystone, J. (2005) "I hate needles" and other factors impacting on travel vaccine uptake. J Travel Med, 12, pp. S41-S46.
37. Cruz, N., Alvarez, X., Specian, RD, Berg, RD and Deitch, EA (1994) Role of mucin, mannose, and beta-1 integrin receptors in Escherichia coli translocation across Caco-2 cell monolayers. Shock, 2, pp. 121-126.
38. Cusi, MG (2001) The response to plasmid DNA-virosome vaccination: A role for circulating antibodies?. Trends Immunol, 22, p. 355.
39. Cusi, MG (2006) Applications of influenza virosomes as a delivery system. Hum Vaccine, 2, pp. 1-7.
40. Cusi, MG, Lomagistro, MM, Valassina, M., Valensin, PE and Gluck, R. (2000) Immunopotentiating of mucosal and systemic antibody responses in mice by intranasal immunization with HLT-combined influenza virosomal vaccine. Vaccine, 18, pp. 2838-2842.
41. Cusi, MG, Zurbriggen, R., Correale, P., Valassina, M., Terrosi, C., Pergola, L., Valensin, PE and Gluck, R. (2002) Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity. Vaccine, 20, pp. 3436-3442.
42. Dabbagh, K., Dahl, ME, Stepick-Biek, P. and Lewis, DB (2002) Toll-like receptor 4 is required for optimal development of Th2 immune responses: Role of dendritic cells. J Immunol, 168, pp. 4524-4530.
43. Daemen, T., de Mare, A., Bungener, L., de Jonge, J., Huckriede, A. and Wilschut, J. (2005) Virosomes for antigen and DNA delivery. Adv Drug Deliv Rev, 57, pp. 451-463.
44. Valserra, M de Bernardi di, Zanasi, A., Ragusa, S., Gluck, R. and Herzog, C. (2002) An open-label comparison of the immunogenicity and tolerability of intranasal and intramuscular formulations of virosomal influenza vaccine in healthy adults. Clin Ther, 24, pp. 100-111.
45. de Haan, A., Tomee, JF, Huchshorn, JP and Wilschut, J. (1995) Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice. Vaccine, 13, pp. 1320-1324.
46. de Jonge, MI, Hamstra, HJ, Jiskoot, W., Roholl, P., Williams, NA, Dankert, J., van Alphen, L. and van der Ley, P. (2004) Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins. Vaccine, 22, pp. 4021-4028.
47. Dodane, V., Khan, M Amin and Merwin, JR (1999) Effect of chitosan on epithelial permeability and structure. Int J Pharm, 182, pp. 21-32.
48. Douce, G., Giuliani, MM, Giannelli, V., Pizza, MG, Rappuoli, R. and Dougan, G. (1998) Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli. Vaccine, 16, pp. 1065-1073.
49. Durrer, P., Gluck, U., Spyr, C., Lang, AB, Zurbriggen, R., Herzog, C. and Gluck, R. (2003) Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine, 21, pp. 4328-4334.
50. Egan, MA, Chong, SY, Hagen, M., Megati, S., Schadeck, EB, Piacente, P., Ma, BJ, Montefiori, DC, Haynes, BF, Israel, ZR, Eldridge, JH and Staats, HF (2004) A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. Vaccine, 22, pp. 3774-3788.
51. Enserink, M. (2000) Radical steps urged to help underserved. Science/ AAAS, 288, pp. 1563-1564.
52. Favre, D. and Viret, JF (2006) Biosafety evaluation of recombinant live oral bacterial vaccines in the context of European regulation. Vaccine, 24, pp. 3856-3864.
53. Feng, L., Qi, XR, Zhou, XJ, Maitani, Y., Wang, SC, Jiang, Y. and Nagai, T. (2006) Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J Control Release, 112, pp. 35-42.
54. Foged, C., Sundblad, A. and Hovgaard, L. (2002) Targeting vaccines to dendritic cells. Pharm Res, 19, pp. 229-238.
55. Foster, N., Clark, MA, Jepson, MA and Hirst, BH (1998) Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo. Vaccine, 16, pp. 536-541.
56. Frankel, G., Lider, O., Hershkoviz, R., Mould, AP, Kachalsky, SG, Candy, DC, Cahalon, L., Humphries, MJ and Dougan, G. (1996) The cell-binding domain of intimin from enteropathogenic Escherichia coli binds to beta1 integrins. J Biol Chem, 271, pp. 20359-20364.
57. Fujimura, Y. (2000) Evidence of M cells as portals of entry for antigens in the nasopharyngeal lymphoid tissue of humans. Virchows Arch, 436, pp. 560-566.
58. Fujimura, Y., Takeda, M., Ikai, H., Haruma, K., Akisada, T., Harada, T., Sakai, T. and Ohuchi, M. (2004) The role of M cells of human nasopharyngeal lymphoid tissue in influenza virus sampling. Virchows Arch, 444, pp. 36-42.
59. Fujimura, Y., Akisada, T., Harada, T. and Haruma, K. (2006) Uptake of microparticles into the epithelium of human nasopharyngeal lymphoid tissue. Med Mol Morphol, 39, pp. 181-186.
60. Gebert, A. (1995) Identification of M-cells in the rabbit tonsil by vimentin immunohistochemistry and in vivo protein transport. Histochem Cell Biol, 104, pp. 211-220.
61. Gebert, A., Willfuhr, B. and Pabst, R. (1995) The rabbit M-cell marker vimentin is present in epithelial cells of the tonsil crypt. Acta Otolaryngol, 115, pp. 697-700.
62. Giannasca, PJ, Boden, JA and Monath, TP (1997) Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins. Infect Immun, 65, pp. 4288-4298.
63. Giudice, EL and Campbell, JD (2006) Needle-free vaccine delivery. Adv Drug Deliv Rev, 58, pp. 68-89.
64. Gluck, U., Gebbers, JO and Gluck, R. (1999) Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J Virol, 73, pp. 7780-7786.
65. Glueck, R. (2001) Review of intranasal influenza vaccine. Adv Drug Deliv Rev, 51, pp. 203-211.
66. Gogev, S., de Fays, K., Versali, MF, Gautier, S. and Thiry, E. (2004) Glycol chitosan improves the efficacy of intranasally administrated replication defective human adenovirus type 5 expressing glycoprotein D of bovine herpesvirus 1. Vaccine, 22, pp. 1946-1953.
67. Gordon, S. (2002) Pattern recognition receptors: Doubling up for the innate immune response. Cell, 111, pp. 927-930.
68. Grabovac, V., Guggi, D. and Bernkop-Schnurch, A. (2005) Comparison of the mucoadhesive properties of various polymers. Adv Drug Deliv Rev, 57, pp. 1713-1723.
69. Gullberg, E., Keita, AV, Salim, SY, Andersson, M., Caldwell, KD, Soderholm, JD and Artursson, P. (2006) Identification of cell adhesion molecules in the human follicle-associated epithelium that improve nanoparticle uptake into the Peyer's patches. J Pharmacol Exp Ther, 319, pp. 632-639.
70. Hak, E., Schonbeck, Y., De Melker, H., Van Essen, GA and Sanders, EA (2005) Negative attitude of highly educated parents and health care workers towards future vaccinations in the Dutch childhood vaccination program. Vaccine, 23, pp. 3103-3107.
71. Harding, CV and Song, R. (1994) Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J Immunol, 153, pp. 4925-4933.
72. Hicks Jr., W., Hall 3rd, L., Sigurdson, L., Stewart, C., Hard, R., Winston, J. and Lwebuga-Mukasa, J. (1997) Isolation and characterization of basal cells from human upper respiratory epithelium. Exp Cell Res, 237, pp. 357-363.
73. Higaki, M., Takase, T., Igarashi, R., Suzuki, Y., Aizawa, C. and Mizushima, Y. (1998) Enhancement of immune response to intranasal influenza HA vaccine by microparticle resin. Vaccine, 16, pp. 741-745.
74. Hilfenhaus, J., Moser, H., Herrmann, A. and Mauler, R. (1982) Herpes simplex virus subunit vaccine: Characterization of the virus strain used and testing of the vaccine. Dev Biol Stand, 52, pp. 321-331.
75. Huckriede, A., Bungener, L., Daemen, T. and Wilschut, J. (2003) Influenza virosomes in vaccine development. Methods Enzymol, 373, pp. 74-91.
76. Huckriede, A., Bungener, L., Stegmann, T., Daemen, T., Medema, J., Palache, AM and Wilschut, J. (2005) The virosome concept for influenza vaccines. Vaccine, 23, pp. S26-S38.
77. Hultgren, SJ, Abraham, S., Caparon, M., Falk, P., Geme 3rd, JW St. and Normark, S. (1993) Pilus and nonpilus bacterial adhesins: Assembly and function in cell recognition. Cell, 73, pp. 887-901.
78. Hussain, N., Jani, PU and Florence, AT (1997) Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat. Pharm Res, 14, pp. 613-618.
79. Ichinohe, T., Watanabe, I., Ito, S., Fujii, H., Moriyama, M., Tamura, S., Takahashi, H., Sawa, H., Chiba, J., Kurata, T., Sata, T. and Hasegawa, H. (2005) Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol, 79, pp. 2910-2919.
80. Illum, L. (2007) Nanoparticulate systems for nasal delivery of drugs: A real improvement over simple systems?. J Pharm Sci, 96, pp. 473-483.
81. Imaoka, K., Miller, CJ, Kubota, M., McChesney, MB, Lohman, B., Yamamoto, M., Fujihashi, K., Someya, K., Honda, M., McGhee, JR and Kiyono, H. (1998) Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues. J Immunol, 161, pp. 5952-5958.
82. Iwasaki, A. and Medzhitov, R. (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol, 5, pp. 987-995.
83. Jabbal-Gill, I., Fisher, AN, Rappuoli, R., Davis, SS and Illum, L. (1998) Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine, 16, pp. 2039-2046.
84. Jaganathan, KS and Vyas, SP (2006) Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine, 24, pp. 4201-4211.
85. Jeong, KI, Suzuki, H., Nakayama, H. and Doi, K. (2000) Ultrastructural study on the follicle-associated epithelium of nasal-associated lymphoid tissue in specific pathogen-free (SPF) and conventional environment-adapted (SPF-CV) rats. J Anat, 196, pp. 443-451.
86. Joseph, A., Louria-Hayon, I., Plis-Finarov, A., Zeira, E., Zakay-Rones, Z., Raz, E., Hayashi, T., Takabayashi, K., Barenholz, Y. and Kedar, E. (2002) Liposomal immunostimulatory DNA sequence (ISS-ODN): An efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine, 20, pp. 3342-3354.
87. Joseph, A., Itskovitz-Cooper, N., Samira, S., Flasterstein, O., Eliyahu, H., Simberg, D., Goldwaser, I., Barenholz, Y. and Kedar, E. (2006) A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Vaccine, 24, pp. 3990-4006.
88. Jung, T., Kamm, W., Breitenbach, A., Hungerer, KD, Hundt, E. and Kissel, T. (2001) Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): Evaluation of antibody response after oral and nasal application in mice. Pharm Res, 18, pp. 352-360.
89. Kaisho, T. and Akira, S. (2002) Toll-like receptors as adjuvant receptors. Biochim Biophys Acta, 1589, pp. 1-13.
90. Kalies, H., Grote, V., Schmitt, HJ and von Kries, R. (2006) Immunisation status of children in Germany: Temporal trends and regional differences. Eur J Pediatr, 165, pp. 30-36.
91. Kaminski, RW, Turbyfill, KR and Oaks, EV (2006) Mucosal adjuvant properties of the Shigella invasin complex. Infect Immun, 74, pp. 2856-2866.
92. Kang, ML, Kang, SG, Jiang, HL, Shin, SW, Lee, DY, Ahn, JM, Rayamahji, N., Park, IK, Shin, SJ, Cho, CS and Yoo, HS (2006) In vivo induction of mucosal immune responses by intranasal administration of chitosan microspheres containing Bordetella bronchiseptica DNT. Eur J Pharm Biopharm, 63, pp. 215-220.
93. Kende, M., Giudice, G Del, Rivera, N. and Hewetson, J. (2006) Enhancement of intranasal vaccination in mice with deglycosylated chain A ricin by LTR72, a novel mucosal adjuvant. Vaccine, 24, pp. 2213-2221.
94. Kodama, S., Abe, N., Hirano, T. and Suzuki, M. (2006) Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant. Laryngoscope, 116, pp. 331-335.
95. Koping-Hoggard, M., Sanchez, A. and Alonso, MJ (2005) Nanoparticles as carriers for nasal vaccine delivery. Expert Rev Vaccines, 4, pp. 185-196.
96. Kwon, YJ, James, E., Shastri, N. and Frechet, JM (2005) In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. Proc Natl Acad Sci USA, 102, pp. 18264-18268.
97. Kwon, YJ, Standley, SM, Goh, SL and Frechet, JM (2005) Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles. J Control Release, 105, pp. 199-212.
98. Kwon, YJ, Standley, SM, Goodwin, AP, Gillies, ER and Frechet, JM (2005) Directed antigen presentation using polymeric microparticulate carriers degradable at lysosomal pH for controlled immune responses. Mol Pharm, 2, pp. 83-91.
99. Kyd, JM, Foxwell, AR and Cripps, AW (2001) Mucosal immunity in the lung and upper airway. Vaccine, 19, pp. 2527-2533.
100. La Rosa, C., Wang, Z., Brewer, JC, Lacey, SF, Villacres, MC, Sharan, R., Krishnan, R., Crooks, M., Markel, S., Maas, R. and Diamond, DJ (2002) Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood, 100, pp. 3681-3689.
101. Lambkin, R., Oxford, JS, Bossuyt, S., Mann, A., Metcalfe, IC, Herzog, C., Viret, JF and Gluck, R. (2004) Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine. Vaccine, 22, pp. 4390-4396.
102. Lanzavecchia, A. (1996) Mechanisms of antigen uptake for presentation. Curr Opin Immunol, 8, pp. 348-354.
103. Lee, YS (1987) Lectin reactivity in human large bowel. Pathology, 19, pp. 397-401.
104. Lee, SE, Kim, SY, Jeong, BC, Kim, YR, Bae, SJ, Ahn, OS, Lee, JJ, Song, HC, Kim, JM, Choy, HE, Chung, SS, Kweon, MN and Rhee, JH (2006) A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun, 74, pp. 694-702.
105. Lenarczyk, A., Le, TT, Drane, D., Malliaros, J., Pearse, M., Hamilton, R., Cox, J., Luft, T., Gardner, J. and Suhrbier, A. (2004) ISCOM based vaccines for cancer immunotherapy. Vaccine, 22, pp. 963-974.
106. Lycke, N. (2005) Targeted vaccine adjuvants based on modified cholera toxin. Curr Mol Med, 5, pp. 591-597.
107. Malliaros, J., Quinn, C., Arnold, FH, Pearse, MJ, Drane, DP, Stewart, TJ and Macfarlan, RI (2004) Association of antigens to ISCOMATRIX adjuvant using metal chelation leads to improved CTL responses. Vaccine, 22, pp. 3968-3975.
108. Marinaro, M., Boyaka, PN, Jackson, RJ, Finkelman, FD, Kiyono, H., Jirillo, E. and McGhee, JR (1999) Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin. J Immunol, 162, pp. 114-121.
109. Mariotti, S., Teloni, R., von Hunolstein, C., Romagnoli, G., Orefici, G. and Nisini, R. (2002) Immunogenicity of anti-Haemophilus influenzae type b CRM197 conjugate following mucosal vaccination with oligodeoxynucleotide containing immunostimulatory sequences as adjuvant. Vaccine, 20, pp. 2229-2239.
110. Matsunaga, Y., Wakatsuki, Y., Tabata, Y., Kawasaki, H., Usui, T., Yoshida, M., Itoh, T., Habu, S. and Kita, T. (2000) Oral immunization with size-purified microsphere beads as a vehicle selectively induces systemic tolerance and sensitization. Vaccine, 19, pp. 579-588.
111. McNeela, EA, O'Connor, D., Jabbal-Gill, I., Illum, L., Davis, SS, Pizza, M., Peppoloni, S., Rappuoli, R. and Mills, KH (2000) A mucosal vaccine against diphtheria: Formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine, 19, pp. 1188-1198.
112. Moldoveanu, Z., Love-Homan, L., Huang, WQ and Krieg, AM (1998) CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine, 16, pp. 1216-1224.
113. Moore, A., McGuirk, P., Adams, S., Jones, WC, McGee, JP, O'Hagan, DT and Mills, KH (1995) Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine, 13, pp. 1741-1749.
114. Morag, A., Morag, B., Bernstein, JM, Beutner, K. and Ogra, PL (1975) In vitro correlates of cell-mediated immunity in human tonsils after natural or induced Rubella virus infection. J Infect Dis, 131, pp. 409-416.
115. Mutsch, M., Zhou, W., Rhodes, P., Bopp, M., Chen, RT, Linder, T., Spyr, C. and Steffen, R. (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med, 350, pp. 896-903.
116. Nagamoto, T., Hattori, Y., Takayama, K. and Maitani, Y. (2004) Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm Res, 21, pp. 671-674.
117. Neutra, MR, Frey, A. and Kraehenbuhl, JP (1996) Epithelial M cells: Gateways for mucosal infection and immunization. Cell, 86, pp. 345-348.
118. Neutra, MR, Pringault, E. and Kraehenbuhl, JP (1996) Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annu Rev Immunol, 14, pp. 275-300.
119. Ninomiya, A., Ogasawara, K., Kajino, K., Takada, A. and Kida, H. (2002) Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice. Vaccine, 20, pp. 3123-3129.
120. Nixon, DF, Hioe, C., Chen, PD, Bian, Z., Kuebler, P., Li, ML, Qiu, H., Li, XM, Singh, M., Richardson, J., McGee, P., Zamb, T., Koff, W., Wang, CY and O'Hagan, D. (1996) Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine, 14, pp. 1523-1530.
121. Ogra, PL (1971) Effect of tonsillectomy and adenoidectomy on nasopharyngeal antibody response to poliovirus. N Engl J Med, 284, pp. 59-64.
122. Ohmura, M., Yamamoto, M., Kiyono, H., Fujihashi, K., Takeda, Y. and McGhee, JR (2001) Highly purified mutant E112K of cholera toxin elicits protective lung mucosal immunity to diphtheria toxin. Vaccine, 20, pp. 756-762.
123. Oliveira, ML, Areas, AP, Campos, IB, Monedero, V., Perez-Martinez, G., Miyaji, EN, Leite, LC, Aires, KA and Ho, P Lee (2006) Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A. Microbes Infect, 8, pp. 1016-1024.
124. Owen, RL and Bhalla, DK (1983) Cytochemical analysis of alkaline phosphatase and esterase activities and of lectin-binding and anionic sites in rat and mouse Peyer's patch M cells. Am J Anat, 168, pp. 199-212.
125. Park, HS, Francis, KP, Yu, J. and Cleary, PP (2003) Membranous cells in nasal-associated lymphoid tissue: A portal of entry for the respiratory mucosal pathogen group A streptococcus. J Immunol, 171, pp. 2532-2537.
126. Partidos, CD, Vohra, P., Anagnostopoulou, C., Jones, DH, Farrar, GH and Steward, MW (1996) Biodegradable microparticles as a delivery system for measles virus cytotoxic T cell epitopes. Mol Immunol, 33, pp. 485-491.
127. Partidos, CD, Vohra, P. and Steward, MW (1996) Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides. Immunology, 87, pp. 179-185.
128. Partidos, CD, Vohra, P., Jones, D., Farrar, G. and Steward, MW (1997) CTL responses induced by a single immunization with peptide encapsulated in biodegradable microparticles. J Immunol Methods, 206, pp. 143-151.
129. Partidos, CD, Vohra, P., Jones, DH, Farrar, G. and Steward, MW (1999) Induction of cytotoxic T-cell responses following oral immunization with synthetic peptides encapsulated in PLG microparticles. J Control Release, 62, pp. 325-332.
130. Pashine, A., Valiante, NM and Ulmer, JB (2005) Targeting the innate immune response with improved vaccine adjuvants. Nat Med, 11, pp. S63-S68.
131. Pearse, MJ and Drane, D. (2005) ISCOMATRIX adjuvant for antigen delivery. Adv Drug Deliv Rev, 57, pp. 465-474.
132. Perez, O., Bracho, G., Lastre, M., Mora, N., Campo, J del, Gil, D., Zayas, C., Acevedo, R., Gonzalez, D., Lopez, JA, Taboada, C., Turtle, C. and Solis, RL (2004) Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern. Immunol Cell Biol, 82, pp. 603-610.
133. Periwal, SB, Kourie, KR, Ramachandaran, N., Blakeney, SJ, DeBruin, S., Zhu, D., Zamb, TJ, Smith, L., Udem, S., Eldridge, JH, Shroff, KE and Reilly, PA (2003) A modified cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine. Vaccine, 21, pp. 376-385.
134. Pine, S., Barackman, J., Ott, G. and O'Hagan, D. (2002) Intranasal immunization with influenza vaccine and a detoxified mutant of heat labile enterotoxin from Escherichia coli (LTK63). J Control Release, 85, pp. 263-270.
135. Poland, GA and Neff, JM (2003) Smallpox vaccine: Problems and prospects. Immunol Allergy Clin North Am, 23, pp. 731-743.
136. Proietti, E., Bracci, L., Puzelli, S., Pucchio, T Di, Sestili, P., De Vincenzi, E., Venditti, M., Capone, I., Seif, I., De Maeyer, E., Tough, D., Donatelli, I. and Belardelli, F. (2002) Type I IFN as a natural adjuvant for a protective immune response: Lessons from the influenza vaccine model. J Immunol, 169, pp. 375-383.
137. Pulendran, B., Kumar, P., Cutler, CW, Mohamadzadeh, M., Van Dyke, T. and Banchereau, J. (2001) Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J Immunol, 167, pp. 5067-5076.
138. Read, RC, Naylor, SC, Potter, CW, Bond, J., Jabbal-Gill, I., Fisher, A., Illum, L. and Jennings, R. (2005) Effective nasal influenza vaccine delivery using chitosan. Vaccine, 23, pp. 4367-4374.
139. Redecke, V., Hacker, H., Datta, SK, Fermin, A., Pitha, PM, Broide, DH and Raz, E. (2004) Cutting edge: Activation of toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J Immunol, 172, pp. 2739-2743.
140. Rharbaoui, F., Drabner, B., Borsutzky, S., Winckler, U., Morr, M., Ensoli, B., Muhlradt, PF and Guzman, CA (2002) The mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur J Immunol, 32, pp. 2857-2865.
141. Rharbaoui, F., Westendorf, A., Link, C., Felk, S., Buer, J., Gunzer, M. and Guzman, CA (2004) The Mycoplasma-derived macrophage-activating 2-kilodalton lipopeptide triggers global immune activation on nasal mucosa-associated lymphoid tissues. Infect Immun, 72, pp. 6978-6986.
142. Rock, KL and Clark, K. (1996) Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. J Immunol, 156, pp. 3721-3726.
143. Rogers, GN and Paulson, JC (1983) Receptor determinants of human and animal influenza virus isolates: Differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology, 127, pp. 361-373.
144. Rumke, HC and Visser, HK (2004) Childhood vaccinations anno 2004. I. Effectiveness and acceptance of the Dutch national vaccination programme. Ned Tijdschr Geneeskd, 148, pp. 356-363.
145. Russell-Jones, GJ, Veitch, H. and Arthur, L. (1999) Lectin-mediated transport of nanoparticles across Caco-2 and OK cells. Int J Pharm, 190, pp. 165-174.
146. Ryan, EJ, McNeela, E., Murphy, GA, Stewart, H., O'Hagan, D., Pizza, M., Rappuoli, R. and Mills, KH (1999) Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: Differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect Immun, 67, pp. 6270-6280.
147. Ryan, EJ, McNeela, E., Pizza, M., Rappuoli, R., O'Neill, L. and Mills, KH (2000) Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: Distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity. J Immunol, 165, pp. 5750-5759.
148. Sanders, MT, Brown, LE, Deliyannis, G. and Pearse, MJ (2005) ISCOM-b based vaccines: The second decade. Immunol Cell Biol, 83, pp. 119-128.
149. Sandri, G., Bonferoni, MC, Rossi, S., Ferrari, F., Gibin, S., Zambito, Y., Colo, G Di and Caramella, C. (2007) Nanoparticles based on N-trimethylchitosan: Evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models. Eur J Pharm Biopharm, 65, pp. 68-77.
150. Sarkar, MA (1992) Drug metabolism in the nasal mucosa. Pharm Res, 9, pp. 1-9.
151. Sbrogio-Almeida, ME and Ferreira, LC (2001) Flagellin expressed by live Salmonella vaccine strains induces distinct antibody responses following delivery via systemic or mucosal immunization routes. FEMS Immunol Med Microbiol, 30, pp. 203-208.
152. Schijns, VE (2000) Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol, 12, pp. 456-463.
153. Schumacher, R., Adamina, M., Zurbriggen, R., Bolli, M., Padovan, E., Zajac, P., Heberer, M. and Spagnoli, GC (2004) Influenza virosomes enhance class I restricted CTL induction through CD4+T cell activation. Vaccine, 22, pp. 714-723.
154. Schwaninger, R., Waelti, E., Zajac, P., Wetterwald, A., Mueller, D. and Gimmi, CD (2004) Virosomes as new carrier system for cancer vaccines. Cancer Immunol Immunother, 53, pp. 1005-1017.
155. Shakweh, M., Besnard, M., Nicolas, V. and Fattal, E. (2005) Poly (lactide-co-glycolide) particles of different physicochemical properties and their uptake by Peyer's patches in mice. Eur J Pharm Biopharm, 61, pp. 1-13.
156. Sharma, R., van Damme, EJ, Peumans, WJ, Sarsfield, P. and Schumacher, U. (1996) Lectin binding reveals divergent carbohydrate expression in human and mouse Peyer's patches. Histochem Cell Biol, 105, pp. 459-465.
157. Shen, H., Ackerman, AL, Cody, V., Giodini, A., Hinson, ER, Cresswell, P., Edelson, RL, Saltzman, WM and Hanlon, DJ (2006) Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology, 117, pp. 78-88.
158. Shephard, MJ, Todd, D., Adair, BM, Po, AL, Mackie, DP and Scott, EM (2003) Immunogenicity of bovine parainfluenza type 3 virus proteins encapsulated in nanoparticle vaccines, following intranasal administration to mice. Res Vet Sci, 74, pp. 187-190.
159. Shimoda, M., Nakamura, T., Takahashi, Y., Asanuma, H., Tamura, S., Kurata, T., Mizuochi, T., Azuma, N., Kanno, C. and Takemori, T. (2001) Isotype-specific selection of high affinity memory B cells in nasal-associated lymphoid tissue. J Exp Med, 194, pp. 1597-1607.
160. Shi, T., Liu, WZ, Gao, F., Shi, GY and Xiao, SD (2005) Intranasal CpG-oligodeoxynucleotide is a potent adjuvant of vaccine against Helicobacter pylori, and T helper 1 type response and interferon-gamma correlate with the protection. Helicobacter, 10, pp. 71-79.
161. Singh, M., Briones, M. and O'Hagan, DT (2001) A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J Control Release, 70, pp. 267-276.
162. Sloat, BR and Cui, Z. (2006) Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli. Vaccine, 24, pp. 6405-6413.
163. Sloat, BR and Cui, Z. (2006) Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharm Res, 23, pp. 1217-1226.
164. Smart, JD (2005) The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev, 57, pp. 1556-1568.
165. Soane, RJ, Hinchcliffe, M., Davis, SS and Illum, L. (2001) Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int J Pharm, 217, pp. 183-191.
166. Staats, HF and Ennis Jr, FA (1999) IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens. J Immunol, 162, pp. 6141-6147.
167. Stewart, TJ, Drane, D., Malliaros, J., Elmer, H., Malcolm, KM, Cox, JC, Edwards, SJ, Frazer, IH and Fernando, GJ (2004) ISCOMATRIX adjuvant: An adjuvant suitable for use in anticancer vaccines. Vaccine, pp. 3738-3743.
168. Storni, T., Kundig, TM, Senti, G. and Johansen, P. (2005) Immunity in response to particulate antigen-delivery systems. Adv Drug Deliv Rev, 57, pp. 333-355.
169. Strindelius, L., Filler, M. and Sjoholm, I. (2004) Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice. Vaccine, 22, pp. 3797-3808.
170. Styers, ML, Kowalczyk, AP and Faundez, V. (2005) Intermediate filaments and vesicular membrane traffic: The odd couple's first dance?. Traffic, 6, pp. 359-365.
171. Szucs, TD and Muller, D. (2005) Influenza vaccination coverage rates in five European countries - a population-based cross-sectional analysis of two consecutive influenza seasons. Vaccine, 23, pp. 5055-5063.
172. Tafaghodi, M., Tabassi, SA Sajadi and Jaafari, MR (2006) Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN. Int J Pharm, 319, pp. 37-43.
173. Takahashi, I., Marinaro, M., Kiyono, H., Jackson, RJ, Nakagawa, I., Fujihashi, K., Hamada, S., Clements, JD, Bost, KL and McGhee, JR (1996) Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis, 173, pp. 627-635.
174. Takahashi, H., Sasaki, K., Takahashi, M., Shigemori, N., Honda, S., Arimitsu, H., Ochi, S., Ohara, N. and Tsuji, T. (2006) Mutant Escherichia coli enterotoxin as a mucosal adjuvant induces specific Th1 responses of CD4+ and CD8+T cells to nasal killed-bacillus calmette-guerin in mice. Vaccine, 24, pp. 3591-3598.
175. Takata, S., Ohtani, O. and Watanabe, Y. (2000) Lectin binding patterns in rat nasal-associated lymphoid tissue (NALT) and the influence of various types of lectin on particle uptake in NALT. Arch Histol Cytol, 63, pp. 305-312.
176. Teloni, R., von Hunolstein, C., Mariotti, S., Donati, S., Orefici, G. and Nisini, R. (2004) Antibody classes and subclasses induced by mucosal immunization of mice with Streptococcus pyogenes M6 protein and oligodeoxynucleotides containing CpG motifs. Indian J Med Res, 119, pp. 126-130.
177. Tong, HH, Liu, X., Chen, Y., James, M. and Demaria, T. (2002) Effect of neuraminidase on receptor-mediated adherence of Streptococcus pneumoniae to chinchilla tracheal epithelium. Acta Otolaryngol, 122, pp. 413-419.
178. Tyrer, P., Foxwell, AR, Cripps, AW, Apicella, MA and Kyd, JM (2006) Microbial pattern recognition receptors mediate M-cell uptake of a gram-negative bacterium. Infect Immun, 74, pp. 625-631.
179. Ugwoke, MI, Agu, RU, Verbeke, N. and Kinget, R. (2005) Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv Drug Deliv Rev, 57, pp. 1640-1665.
180. van der Ven, I. and Sminia, T. (1993) The development and structure of mouse nasal-associated lymphoid tissue: An immuno- and enzyme-histochemical study. Reg Immunol, 5, pp. 69-75.
181. van Ginkel, FW, Jackson, RJ, Yoshino, N., Hagiwara, Y., Metzger, DJ, Connell, TD, Vu, HL, Martin, M., Fujihashi, K. and McGhee, JR (2005) Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect Immun, 73, pp. 6892-6902.
182. Vila, A., Sanchez, A., Tobio, M., Calvo, P. and Alonso, MJ (2002) Design of biodegradable particles for protein delivery. J Control Release, 78, pp. 15-24.
183. Vila, A., Sanchez, A., Evora, C., Soriano, I., McCallion, O. and Alonso, MJ (2005) PLA-PEG particles as nasal protein carriers: The influence of the particle size. Int J Pharm, 292, pp. 43-52.
184. Wang, X., Kochetkova, I., Haddad, A., Hoyt, T., Hone, DM and Pascual, DW (2005) Transgene vaccination using Ulex europaeus agglutinin I (UEA-1) for targeted mucosal immunization against HIV-1 envelope. Vaccine, 23, pp. 3836-3842.
185. Wang, Q., McLoughlin, RM, Cobb, BA, Charrel-Dennis, M., Zaleski, KJ, Golenbock, D., Tzianabos, AO and Kasper, DL (2006) A bacterial carbohydrate links innate and adaptive responses through toll-like receptor 2. J Exp Med, 203, pp. 2853-2863.
186. Watson, CJ, Rowland, M. and Warhurst, G. (2001) Functional modeling of tight junctions in intestinal cell monolayers using polyethylene glycol oligomers. Am J Physiol Cell Physiol, 281, pp. C388-C397.
187. Xiang, SD, Scholzen, A., Minigo, G., David, C., Apostolopoulos, V. and Mottram, PL (2006) Pathogen recognition and development of particulate vaccines: Does size matter?. Methods, 40, pp. 1-9.
188. Yamamoto, S., Kiyono, H., Yamamoto, M., Imaoka, K., Fujihashi, K., Van Ginkel, FW, Noda, M., Takeda, Y. and McGhee, JR (1997) A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci USA, 94, pp. 5267-5272.
189. Yamamoto, M., Briles, DE, Yamamoto, S., Ohmura, M., Kiyono, H. and McGhee, JR (1998) A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J Immunol, 161, pp. 4115-4121.
190. Yamamoto, M., Kiyono, H., Yamamoto, S., Batanero, E., Kweon, MN, Otake, S., Azuma, M., Takeda, Y. and McGhee, JR (1999) Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant. J Immunol, 162, pp. 7015-7021.
191. Yamamoto, M., Kiyono, H., Kweon, MN, Yamamoto, S., Fujihashi, K., Kurazono, H., Imaoka, K., Bluethmann, H., Takahashi, I., Takeda, Y., Azuma, M. and McGhee, JR (2000) Enterotoxin adjuvants have direct effects on T cells and antigen-presenting cells that result in either interleukin-4-dependent or-independent immune responses. J Infect Dis, 182, pp. 180-190.
192. Yamamoto, M., McGhee, JR, Hagiwara, Y., Otake, S. and Kiyono, H. (2001) Genetically manipulated bacterial toxin as a new generation mucosal adjuvant. Scand J Immunol, 53, pp. 211-217.
193. Yuki, Y. and Kiyono, H. (2003) New generation of mucosal adjuvants for the induction of protective immunity. Rev Med Virol, 13, pp. 293-310.
194. Zuercher, AW, Coffin, SE, Thurnheer, MC, Fundova, P. and Cebra, JJ (2002) Nasal-associated lymphoid tissue is a mucosal inductive site for virus-specific humoral and cellular immune responses. J Immunol, 168, pp. 1796-1803.